Moderna Therapeutics, Inc. v. Arbutus Biopharma Corporation

Track this case

Case Number:

IPR2019-00554

Case Type:

IPR

Status:

Final Written Decision

Petitioner:

Moderna Therapeutics, Inc.

Patent Owner:

Arbutus Biopharma Corporation

Tech Center:

1600

  1. July 23, 2020

    Moderna Can't Invalidate Drug-Delivery Composition Patent

    The Patent Trial and Appeal Board ruled Thursday that Moderna Therapeutics Inc. failed to invalidate claims in Arbutus Biopharma Corp.'s patent covering a drug-delivery composition as obvious or anticipated based on overlapping composition ranges, finding that prior art does not explicitly disclose such ranges.

  2. April 22, 2020

    PTAB Weighs Obviousness Standard In Gene Therapy Case

    The Patent Trial and Appeal Board wrestled Wednesday with Arbutus Biopharma's argument that its rival failed to prove that claims in its patent covering a drug delivery composition are obvious on their face because their formulations overlap with those disclosed in existing technology.

  3. July 25, 2019

    PTAB Will Review Hep B Treatment Co.'s Patent

    The Patent Trial and Appeal Board has agreed to review a drug delivery formulation patent owned by Arbutus Biopharma Corp., a company set on curing hepatitis B.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!